Zhuhai Livzon Gene Detection Technology Co. Ltd.

Zhuhai Livzon Gene Detection Technology Co. Ltd.

Zhuhai Livzon Gene Detection Technology Co., Ltd. (hereafter referred to Livzon Gene) was founded in December 2016. It is a holding subsidiary of the Livzon Pharmaceutical Group that specializes in precision medical testing. By combining testing products with precision therapy medicines for the diagnosis and treatment of malignancies, Livzon Pharmaceutical Group took the lead in the field of precision medicine. As an important part of the Group’s comprehensive strategy for precision medicine, Livzon Gene provides precision testing services with international advanced technologies, it is in the process of developing world-leading chain specialty laboratories.

Livzon Gene created the Livzon (Zhuhai) Medical Testing Laboratory, which has obtained medical service qualification. The company has 5 platforms for accurate detection of malignancies: Liquid Biopsy, Illumina Genome Analyzer IIx, Fluorescent PCR, Pathologic Diagnosis, and Immunodetection. The company’s services include tumor LiquidBiopsy, Drug Companion Diagnostic, Gene Testing of Tumor Tissue, Genetic Screening for Cancer, and Drug Sensitivity Testing. LiquidBiopsy is the world’s first platform for direct sequencing of circulating tumor cells. The special project, “circulating tumor cells/circulating tumor DNA/white blood cell 3-mode version combined sequencing” will one day provide comprehensive tumor molecular information.

Livzon Gene always serves the needs of patients and doctors, and provides comprehensive, advanced, precise, and rapid testing services for the benefit of human health.